Literature DB >> 20565291

Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.

Kerrie Vaughan1, Jason Greenbaum, Martin Blythe, Bjoern Peters, Alessandro Sette.   

Abstract

A meta-analysis was performed in order to inventory the immune epitope data related to viruses in the genus Flavivirus. Nearly 2000 epitopes were captured from over 130 individual Flavivirus-related references identified from PubMed and reported as of September 2009. This report includes all epitope structures and associated immune reactivity from the past and current literature, including: the epitope distribution among pathogens and related strains, the epitope distribution among different pathogen antigens, the number of epitopes defined in human and animal models of disease, the relationship between epitopes identified in different disease states following natural (or experimental) infection, and data from studies focused on candidate vaccines. We found that the majority of epitopes were defined for dengue virus (DENV) and West Nile virus (WNV). The prominence of DENV and WNV data in the epitope literature is likely a reflection of their overall worldwide impact on human disease, and the lack of vaccines. Conversely, the relatively smaller number of epitopes defined for the other viruses within the genus (yellow fever and Japanese encephalitis virus) most likely reflects the presence of established prophylaxis and/or their more modest impact on morbidity and mortality globally. Through this work we hope to provide useful data to those working in the area of Flavivirus research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20565291      PMCID: PMC2942863          DOI: 10.1089/vim.2010.0006

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  104 in total

1.  Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?

Authors:  H Loke; D B Bethell; C X Phuong; M Dung; J Schneider; N J White; N P Day; J Farrar; A V Hill
Journal:  J Infect Dis       Date:  2001-11-13       Impact factor: 5.226

2.  Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection.

Authors:  S B Halstead; H Shotwell; J Casals
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

3.  Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies.

Authors:  R B Tesh; H Guzman; A P da Rosa; P F Vasconcelos; L B Dias; J E Bunnell; H Zhang; S Y Xiao
Journal:  J Infect Dis       Date:  2001-04-17       Impact factor: 5.226

4.  Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.

Authors:  T R Kreil; M M Eibl
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design.

Authors:  Andrew K I Falconar
Journal:  Clin Vaccine Immunol       Date:  2007-02-28

6.  Dengue virus evolution and virulence models.

Authors:  Rebeca Rico-Hesse
Journal:  Clin Infect Dis       Date:  2007-04-18       Impact factor: 9.079

7.  Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones.

Authors:  S J Gagnon; W Zeng; I Kurane; F A Ennis
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

Authors:  Michael S Diamond; Bimmi Shrestha; Anantha Marri; Darby Mahan; Michael Engle
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice.

Authors:  M J Wallace; D W Smith; A K Broom; J S Mackenzie; R A Hall; G R Shellam; P C McMinn
Journal:  J Gen Virol       Date:  2003-07       Impact factor: 3.891

Review 10.  Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development.

Authors:  Theodore C Pierson; Daved H Fremont; Richard J Kuhn; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

View more
  28 in total

1.  NIAID workshop on Flavivirus immunity.

Authors:  Alison D Augustine; M Cristina Cassetti; Francis A Ennis; Eva Harris; William H Hildebrand; Patricia M Repik
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

2.  Reproducibility and conflicts in immune epitope data.

Authors:  Randi Vita; Nicole Vasilevsky; Anita Bandrowski; Melissa Haendel; Alessandro Sette; Bjoern Peters
Journal:  Immunology       Date:  2016-02-05       Impact factor: 7.397

Review 3.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

4.  Experimental inoculation of Artibeus jamaicensis bats with dengue virus serotypes 1 or 4 showed no evidence of sustained replication.

Authors:  Salomé Cabrera-Romo; Benito Recio-Tótoro; Ana C Alcalá; Humberto Lanz; Rosa María del Ángel; Victor Sánchez-Cordero; Ángel Rodríguez-Moreno; Juan E Ludert
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

5.  Analysis of T cell responses to the major allergens from German cockroach: epitope specificity and relationship to IgE production.

Authors:  Carla Oseroff; John Sidney; Victoria Tripple; Howard Grey; Robert Wood; David H Broide; Jason Greenbaum; Ravi Kolla; Bjoern Peters; Anna Pomés; Alessandro Sette
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

6.  Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants.

Authors:  Qiang Chen; Junyun He; Waranyoo Phoolcharoen; Hugh S Mason
Journal:  Hum Vaccin       Date:  2011-03-01

7.  T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts.

Authors:  Carla Oseroff; John Sidney; Randi Vita; Victoria Tripple; Denise M McKinney; Scott Southwood; Tess M Brodie; Federica Sallusto; Howard Grey; Rafeul Alam; David Broide; Jason A Greenbaum; Ravi Kolla; Bjoern Peters; Alessandro Sette
Journal:  J Immunol       Date:  2012-07-11       Impact factor: 5.422

8.  Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.

Authors:  Laura Rivino; Emmanuelle A P Kumaran; Vojislav Jovanovic; Karen Nadua; En Wei Teo; Shyue Wei Pang; Guo Hui Teo; Victor Chih Hao Gan; David C Lye; Yee Sin Leo; Brendon J Hanson; Kenneth G C Smith; Antonio Bertoletti; David M Kemeny; Paul A MacAry
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.

Authors:  Xiao-Feng Li; Yong-Qiang Deng; Hui-Qiang Yang; Hui Zhao; Tao Jiang; Xue-Dong Yu; Shi-Hua Li; Qing Ye; Shun-Ya Zhu; Hong-Jiang Wang; Yu Zhang; Jie Ma; Yong-Xin Yu; Zhong-Yu Liu; Yu-Hua Li; E-De Qin; Pei-Yong Shi; Cheng-Feng Qin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

10.  B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.

Authors:  Lalita Priyamvada; Alice Cho; Nattawat Onlamoon; Nai-Ying Zheng; Min Huang; Yevgeniy Kovalenkov; Kulkanya Chokephaibulkit; Nasikarn Angkasekwinai; Kovit Pattanapanyasat; Rafi Ahmed; Patrick C Wilson; Jens Wrammert
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.